Timothy Ashby

Dr. Timothy Ashby serves as an Assistant Professor in the Department of Biomedical Informatics within the College of Medicine at the University of Arkansas for Medical Sciences (UAMS). His research focuses on genomic and computational approaches to understanding multiple myeloma pathogenesis, tumor microenvironment interactions, and therapeutic resistance mechanisms. Supported by a TRI KL2 Scholars award as Principal Investigator, his work integrates multi-omics data to identify novel therapeutic targets and improve risk stratification.

Dr. Ashby's research interests center on cancer genomics and biomedical informatics applications in multiple myeloma. His laboratory investigates spatial genomic heterogeneity, drug resistance mechanisms mediated by tumor-stromal interactions, and epigenetic drivers of high-risk disease. Current projects include characterizing NOTCH3-CXCL12 signaling axes in chemoresistance, developing bispecific CAR-T therapies targeting BCMA/CD24, and creating genomic risk stratification systems for transplant patients.

Analysis of his 15 most recent publications reveals dominant themes in tumor microenvironment crosstalk (73% of articles), genomic instability drivers (60%), and therapeutic resistance mechanisms (87%). His work increasingly incorporates multi-omics integration (40% of recent papers) and clinical translation of genomic findings (33%).

Scientific recognition includes:

• TRI KL2 Scholars award (Principal Investigator, 2022-2024)

Dr. Ashby actively participates in major myeloma research initiatives as Co-Investigator on multiple significant grants including:

• US Department of Defense grant W81XWH-19-1-0500 (2020-2024) targeting CD24+ tumor-initiating cells
• NIH R01CA209882 (2017-2028) investigating osteocyte contributions to myeloma bone disease

His collaborative network includes leading myeloma researchers at UAMS and national institutions, with particular emphasis on translating genomic findings into clinical applications.

His research is conducted within the UAMS Myeloma Multidisciplinary Team, which includes clinicians, basic scientists, and bioinformaticians focused on precision oncology approaches. Current efforts involve developing clinical genomic classifiers and validating novel therapeutic targets identified through his group's computational analyses.